Clinical trials: Adult Atopic Dermatitis
Dermatitis, Atopic, Pruritus
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: What is the efficacy and safety of ASN008? What is the impact of ASN008 on itch in patients…
- Trial name
- NCT05870865
- Testing
- ASN008, ASN008 Matching Vehicle
- Where
- 27 sites in United States
- Volunteers
- 144 people
- Sponsor
- Formation Bio, Inc.
Atopic Dermatitis
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and…
- Trial name
- TRuE-AD4 (NCT06238817)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 241 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
- Trial name
- NCT03745638
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 631 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis (AD)
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
- Trial name
- NCT02357940
- Testing
- Experimental Product
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis
Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.
This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the…
- Trial name
- NCT03725722
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 251 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are…
- Trial name
- GECKO (NCT03864627)
- Testing
- MOR106
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
- Trial name
- ADapt (NCT05369403)
- Testing
- Lebrikizumab
- Where
- 37 sites in United States
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with…
- Trial name
- NCT03738423
- Testing
- REGN3500
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 129 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD)…
- Trial name
- AD Up (NCT03568318)
- Testing
- Upadacitinib, Topical corticosteroids (TCS)
- Where
- 193 sites in United States, Australia and 22 more
- Volunteers
- 1,533 people
- Sponsor
- AbbVie
Atopic Dermatitis
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Phase 2 study of RPT193 in adults with atopic dermatitis
- Trial name
- NCT05399368
- Testing
- RPT193
- Where
- 59 sites in United States, Canada
- Volunteers
- 229 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Atopic Dermatitis
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD).
- Trial name
- NCT00723489
- Testing
- Live Yellow Fever Vaccine (YFV-17D)
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D
Dermatitis
Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam
The scope of this open label clinical trial is to evaluate and confirm the performance of DermoRelizema ecofoam in the improvement of the dermatitis severity, by alleviating the symptomatology.
- Trial name
- NCT04826471
- Testing
- DermoRelizema ecofoam
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Researchers are looking for a better way to treat atopic dermatitis (AD), an often long-lasting inflammation of the skin. Atopic dermatitis, also called eczema, is causing patches of skin to become swollen, red, cracked, and…
- Trial name
- Damask (NCT05656911)
- Testing
- Zabedosertib (BAY1834845)
- Where
- 22 sites in United States, Czechia and 5 more
- Volunteers
- 77 people
- Sponsor
- Bayer
Atopic Dermatitis, Healthy Volunteers
Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis
This study is a single dose escalation study of tezepelumab (AMG 157) in healthy adults (Part A) and adults with moderate to severe atopic dermatitis (Part B).
- Trial name
- NCT00757042
- Testing
- Tezepelumab
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Amgen
Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity.
- Trial name
- NCT05001139
- Testing
- Relizema ecofoam
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis ([AD]; skin rash, inflammation) that is…
- Trial name
- NCT00455429
- Testing
- JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily
- Where
- 19 sites in United States
- Volunteers
- 84 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
- Trial name
- NCT03011892
- Testing
- Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD
- Where
- 52 sites in United States, Canada
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately…
- Trial name
- NCT02755649
- Testing
- Dupilumab
- Where
- 73 sites in Austria, Belgium and 8 more
- Volunteers
- 325 people
- Sponsor
- Regeneron Pharmaceuticals